1c:{"metadata":[["$","title","0",{"children":"NIH VideoCast - Inflammatory Breast Cancer: Genetic Determinants and Challenges for Novel Therapeutics"}],["$","meta","1",{"name":"description","content":"The NIH Director's Wednesday Afternoon Lecture Series \n

\nInflammatory breast cancer is the most lethal form of breast cancer with a 10-yr disease free survival of less 25% compared to 65% for all invasive breast cancers. Two genes appear to be important determinants of this aggressive breast cancer phenotype: The oncogene RhoC and the tumor suppressor gene WISP3. When acting in concert, over-expression of RhoC and loss of WISP3 cooperate to create an inflammatory-like phenotype in breast cells. As markers of poor prognosis, it is our challenge to target these alterations to arrive at a rational therapy for aggressive breast cancer phenotypes.\n

\nFor more information, visit
\nSofia Merajver
\n"}],["$","meta","2",{"name":"publisher","content":"National Institutes of Health"}],["$","meta","3",{"property":"og:title","content":"NIH VideoCast - Inflammatory Breast Cancer: Genetic Determinants and Challenges for Novel Therapeutics"}],["$","meta","4",{"property":"og:description","content":"The NIH Director's Wednesday Afternoon Lecture Series \n

\nInflammatory breast cancer is the most lethal form of breast cancer with a 10-yr disease free survival of less 25% compared to 65% for all invasive breast cancers. Two genes appear to be important determinants of this aggressive breast cancer phenotype: The oncogene RhoC and the tumor suppressor gene WISP3. When acting in concert, over-expression of RhoC and loss of WISP3 cooperate to create an inflammatory-like phenotype in breast cells. As markers of poor prognosis, it is our challenge to target these alterations to arrive at a rational therapy for aggressive breast cancer phenotypes.\n

\nFor more information, visit
\nSofia Merajver
\n"}],["$","meta","5",{"property":"og:url","content":"https://uat.d1rkikwu4q8tg.amplifyapp.com/watch/96d54c67-d5db-11f0-9cf9-12c45c580ad9"}],["$","meta","6",{"property":"og:site_name","content":"NIH VideoCast"}],["$","meta","7",{"property":"og:image","content":"https://nihcit.rev.vbrick.com/api/v2/media/videos/thumbnails/dd3b5321-3fbe-4f8a-953f-dec621b00743.jpg"}],["$","meta","8",{"property":"og:type","content":"website"}],["$","meta","9",{"name":"twitter:card","content":"summary_large_image"}],["$","meta","10",{"name":"twitter:title","content":"NIH VideoCast - Inflammatory Breast Cancer: Genetic Determinants and Challenges for Novel Therapeutics"}],["$","meta","11",{"name":"twitter:description","content":"The NIH Director's Wednesday Afternoon Lecture Series \n

\nInflammatory breast cancer is the most lethal form of breast cancer with a 10-yr disease free survival of less 25% compared to 65% for all invasive breast cancers. Two genes appear to be important determinants of this aggressive breast cancer phenotype: The oncogene RhoC and the tumor suppressor gene WISP3. When acting in concert, over-expression of RhoC and loss of WISP3 cooperate to create an inflammatory-like phenotype in breast cells. As markers of poor prognosis, it is our challenge to target these alterations to arrive at a rational therapy for aggressive breast cancer phenotypes.\n

\nFor more information, visit
\nSofia Merajver
\n"}],"$L22","$L23","$L24"],"error":null,"digest":"$undefined"}